• OPEN AN ACCOUNT
Indian Indices
Sensex
84,233.64 -40.28
( -0.05%)
Global Indices
Nasdaq
50,155.23 -53.92
(-0.11%)
Dow Jones
6,964.65 1.84
(0.03%)
Hang Seng
57,678.97 1,315.03
(2.33%)
Nikkei 225
10,491.19 137.35
(1.33%)
Forex
USD-INR
90.66 0.22
(0.24%)
EUR-INR
107.64 0.80
(0.75%)
GBP-INR
123.65 0.62
(0.51%)
JPY-INR
0.58 0.00
(0.85%)

EQUITY - MARKET SCREENER

Glenmark Pharmaceuticals Ltd
Industry :  Pharmaceuticals - Indian - Bulk Drugs & Formln
BSE Code
ISIN Demat
Book Value()
532296
INE935A01035
848.3143291
NSE Symbol
P/E(TTM)
Mar.Cap( Cr.)
GLENMARK
38.34
56876.16
EPS(TTM)
Face Value()
Div & Yield %
52.57
1
0.12
 

Board of SG Finserve approves investment of Rs 400 cr in setting up subsidiaries
Jan 23,2026
The board of SG Finserve at its meeting held on 23 January 2026 has approved an investment plan of up to Rs 400 crore for setting up subsidiaries of the company, proposed to be incorporated.

The proposed subsidiaries, subject to applicable regulatory and statutory approvals shall, interalia, be engaged in the following activities:

(i) Asset Reconstruction Company (ARC);
(ii) Investment Manager and/or Sponsor for setting up of a Category III Alternate Investment Fund;
(iii) Insurance Broking (life and non-life); and
iv) Information Technology services, including LOS, LMS, and a digital marketplace.

Out of the total approved investment, the regulatory minimum capital requirement for setting up an ARC is expected to be Rs 300 crore, to be infused in accordance with applicable regulations.